Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Ledergerber

Showing results (61-70 of 113) with videos related to

Pageof 12
Sort By:
Journal of Internal Medicine|February 20, 2007
HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapyJ A C Sterne, M May, H C Bucher, et al.
HIV Medicine|April 21, 2021
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort StudyH Kovari, B Surial, P E Tarr, et al.
JAMA|April 13, 1994
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study GroupJ D Lundgren, A N Phillips, C Pedersen, et al.
Lancet (London, England)|July 31, 2007
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort studyA Mocroft, A N Phillips, J Gatell, et al.
BMJ (Clinical Research Ed.)|April 23, 1994
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study GroupJ D Lundgren, C Pedersen, N Clumeck, et al.
HIV Medicine|March 6, 2010
History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment changeJ Reekie, A Mocroft, B Ledergerber, et al.
HIV Medicine|August 16, 2014
Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort StudyR Weber, M Huber, M Battegay, et al.
Archives of Internal Medicine|July 10, 1999
Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort StudyR Weber, B Ledergerber, R Zbinden, et al.
HIV Medicine|September 8, 2009
Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS)A U Scherrer, B Hasse, V von Wyl, et al.
Lancet (London, England)|October 31, 2001
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort StudyJ Fellay, K Boubaker, B Ledergerber, et al.
Pageof 12

Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
Journal of Internal Medicine|February 20, 2007
HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapyJ A C Sterne, M May, H C Bucher, et al.
HIV Medicine|April 21, 2021
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort StudyH Kovari, B Surial, P E Tarr, et al.
JAMA|April 13, 1994
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study GroupJ D Lundgren, A N Phillips, C Pedersen, et al.
Lancet (London, England)|July 31, 2007
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort studyA Mocroft, A N Phillips, J Gatell, et al.
BMJ (Clinical Research Ed.)|April 23, 1994
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study GroupJ D Lundgren, C Pedersen, N Clumeck, et al.
HIV Medicine|March 6, 2010
History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment changeJ Reekie, A Mocroft, B Ledergerber, et al.
HIV Medicine|August 16, 2014
Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort StudyR Weber, M Huber, M Battegay, et al.
Archives of Internal Medicine|July 10, 1999
Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort StudyR Weber, B Ledergerber, R Zbinden, et al.
HIV Medicine|September 8, 2009
Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS)A U Scherrer, B Hasse, V von Wyl, et al.
Lancet (London, England)|October 31, 2001
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort StudyJ Fellay, K Boubaker, B Ledergerber, et al.
Pageof 12